Literature DB >> 10048679

Etiology and treatment of community-acquired pneumonia in ambulatory children.

L Wubbel1, L Muniz, A Ahmed, M Trujillo, C Carubelli, C McCoig, T Abramo, M Leinonen, G H McCracken.   

Abstract

OBJECTIVES: To determine the etiology of community-acquired pneumonia in ambulatory children and to compare responses to treatment with azithromycin, amoxicillin-clavulanate or erythromycin estolate.
METHODS: Ambulatory patients with pneumonia were identified at the Children's Medical Center of Dallas, TX. Children age 6 months to 16 years with radiographic and clinical evidence of pneumonia were enrolled and randomized to receive either azithromycin suspension for 5 days or a 10-day course of amoxicillin-clavulanate for those <5 years or erythromycin estolate suspension for those > or = 5 years. Blood culture was obtained in all patients and we obtained nasopharyngeal and pharyngeal swabs for culture and polymerase chain reaction (PCR) testing for Chlamydia pneumoniae and Mycoplasma pneumoniae and nasopharyngeal swabs for viral direct fluorescent antibody and culture. Acute and convalescent serum specimens were tested for antibodies to C. pneumoniae, M. pneumoniae and Streptococcus pneumoniae. Patients were evaluated 10 to 37 days later when repeat specimens for serology, PCR and culture were obtained. For comparative purposes healthy children attending the well-child clinic had nasopharyngeal and pharyngeal swabs obtained for PCR and culture for C. pneumoniae and M. pneumoniae.
RESULTS: Between February, 1996, and December, 1997, we enrolled 174 patients, 168 of whom fulfilled protocol criteria for evaluation. There were 55% males and 63% were <5 years of age. All blood cultures were sterile and there was no correlation between the white blood cell and differential counts and etiology of pneumonia. Etiologic agents were identified in 73 (43%) of 168 patients. Infection was attributed to M. pneumoniae in 7% (12 of 168), C. pneumoniae in 6% (10 of 168), S. pneumoniae in 27% (35 of 129) and viruses in 20% (31 of 157). None of the swab specimens from 75 healthy control children was positive for C. pneumoniae or M. pneumoniae. Clinical response to therapy was similar for the three antibiotic regimens evaluated, including those with infection attributed to bacterial agents.
CONCLUSION: Although a possible microbial etiology was identified in 43% of the evaluable patients, clinical findings and results of blood cultures, chest radiographs and white blood cell and differential counts did not distinguish patients with a defined etiology from those without a known cause for pneumonia. There were no differences in the clinical responses of patients to the antimicrobial regimens studied.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048679     DOI: 10.1097/00006454-199902000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  61 in total

1.  British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood.

Authors: 
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

Review 2.  Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections.

Authors:  K Loens; D Ursi; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

3.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 4.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 5.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Penicillin and gentamicin therapy vs amoxicillin/clavulanate in severe hypoxemic pneumonia.

Authors:  Arun Bansal; Sunit C Singhi; M Jayashree
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 1.967

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 9.  Community-acquired pneumonia in children: issues in optimizing antibacterial treatment.

Authors:  Matti Korppi
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Epidemiological and economic burden of pneumococcal diseases in Canadian children.

Authors:  Geneviève Petit; Philippe De Wals; Barbara Law; Theresa Tam; Lonny James Erickson; Maryse Guay; Alicia Framarin
Journal:  Can J Infect Dis       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.